Non-opioid Pain Patches Market

2019 Analysis and Review of Non-opioid Pain Patches Market by Product Type - Lidocaine Patches, Diclofenac Patches, Methyl Salicylate Patches, Capsaicin Patches, Ketoprofen Patches, and Others for 2019-2029

Lidocaine Patches Continue to Shape Value Creation

Market players continue to invest in manufacturing lidocaine patches, which would generate greater total return to shareholders (TRS). Benefits of lidocaine patches - superior topical effectiveness with minimal side effects and prolong transdermal drug release - are enabling their broader application.

By 2029, lidocaine patches worth over US$ 3 Bn will be leveraged in treating chronic pain conditions. Influenced by these numbers, manufacturers are indulging in continuous R&D activities to develop lidocaine-based non-opioid pain patches.

North America Represents Most Prospective Market

The U.S. Department of Health and Human Services (HHS) has found that, pain-related conditions are the most common reason for frequent hospital visits in the U.S. Further, the Centers for Disease Control and Prevention has underlined opioid misuse as among various factors burdening the national economy, every year. These trends are underpinning the non-opioid pain patches market in North America.

To curb expenses incurred for addiction treatment, governments in this developed region are introducing regulations to speed up the approval of novel non-opioid pain patches for chronic pain treatment. This study further reveals that, the North America non-opioid pain patches will hit US$ 2 Bn in 2022.

Manufacturers Must Focus on Developing Topical Therapeutics

Given the addictive vulnerability of opioid analgesics, manufacturers are turning to the development of non-addictive topical pain patches for acute as well as chronic pain. These novel new alternative therapeutics are developed with an aim to increase the duration of analgesic action and improved skin adhesion.

For instance, Sorrento Therapeutics has developed the ZTlido (lidocaine topical pain patch) 1.8% patch that can deliver pain relief for up to 12 hours, including during workout sessions. The product has been approved for the treatment of pain associated with post-herpetic neuralgia (PHA)

How Growth will Unfold

Majority of non-opioid pain patches are available as over-the-counter (OTC) products, and are purchased across various distribution channels according to a physician’s suggestion. Conventionally, hospitals have been accounting for substantial sales of non-opioid pain patches, attributable to frequent patient visits for pain management, especially musculoskeletal disorders.

Moreover, the prolonged consumption of painkillers triggers medication-related adverse effects, and, as such, physicians prescribe these patches as an alternative to oral drugs. However, in developed regions, consumers prefer retail pharmacies and drug stores for purchasing OTC pain medication drugs and prescription medicines. Market players are thus uncovering new revenue lines through these distribution channels, which will outperform hospitals in 2024, in terms of value share.


The global non-opioid pain patches market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type 

  • Lidocaine Patches
  • Diclofenac Patches
  • Methyl Salicylate Patches
  • Capsaicin Patches
  • Ketoprofen Patches
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies


  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa 

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports


Non-opioid Pain Patches Market